Total Payments
$192,897
2024 Payments
$127,470
Companies
36
Transactions
378
Medicare Patients
1,667
Medicare Billing
$222,077
Payment Breakdown by Category
Other$159,046 (82.5%)
Consulting$22,141 (11.5%)
Food & Beverage$8,117 (4.2%)
Travel$3,589 (1.9%)
Education$3.31 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for serving as faculty or as a speaker for a medical education program | $91,260 | 59 | 47.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $67,786 | 31 | 35.1% |
| Consulting Fee | $22,141 | 10 | 11.5% |
| Food and Beverage | $8,117 | 263 | 4.2% |
| Travel and Lodging | $3,589 | 14 | 1.9% |
| Education | $3.31 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eisai Inc. | $147,982 | 146 | $0 (2024) |
| Biogen, Inc. | $26,339 | 24 | $0 (2024) |
| Lilly USA, LLC | $12,444 | 30 | $0 (2024) |
| OnMark, Inc. | $1,400 | 1 | $0 (2024) |
| Corium, LLC | $1,134 | 10 | $0 (2023) |
| Janssen Pharmaceuticals, Inc | $519.27 | 27 | $0 (2024) |
| Neurocrine Biosciences, Inc. | $436.88 | 18 | $0 (2024) |
| Lundbeck LLC | $432.61 | 19 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $408.37 | 22 | $0 (2024) |
| ACADIA Pharmaceuticals Inc | $349.76 | 17 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $127,470 | 164 | Eisai Inc. ($112,852) |
| 2023 | $35,234 | 75 | Eisai Inc. ($33,290) |
| 2022 | $1,187 | 59 | Janssen Pharmaceuticals, Inc ($179.14) |
| 2021 | $22,659 | 52 | Biogen, Inc. ($21,941) |
| 2020 | $4,366 | 5 | Biogen, Inc. ($4,342) |
| 2019 | $1,836 | 19 | Eisai Inc. ($1,661) |
| 2018 | $19.64 | 1 | Mitsubishi Tanabe Pharma America, Inc. ($19.64) |
| 2017 | $125.65 | 3 | GENZYME CORPORATION ($97.86) |
All Payment Transactions
378 individual payment records from CMS Open Payments — Page 1 of 16
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Eisai Inc. | Leqembi (Drug) | Consulting Fee | Cash or cash equivalent | $585.00 | General |
| Category: Neurology | ||||||
| 12/16/2024 | Lilly USA, LLC | KISUNLA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,600.00 | General |
| Category: Neuroscience | ||||||
| 12/16/2024 | Lilly USA, LLC | KISUNLA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $600.00 | General |
| Category: Neuroscience | ||||||
| 12/16/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $18.90 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 12/13/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $16.87 | General |
| Category: Central Nervous System | ||||||
| 12/11/2024 | Lilly USA, LLC | KISUNLA (Drug) | Food and Beverage | In-kind items and services | $32.26 | General |
| Category: Neuroscience | ||||||
| 12/05/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $27.98 | General |
| Category: Neurology | ||||||
| 11/21/2024 | Eisai Inc. | Leqembi (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $1,755.00 | General |
| Category: Neurology | ||||||
| 11/21/2024 | Eisai Inc. | Leqembi (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $1,462.50 | General |
| Category: Neurology | ||||||
| 11/21/2024 | Eisai Inc. | Leqembi (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $1,462.50 | General |
| Category: Neurology | ||||||
| 11/21/2024 | Eisai Inc. | Leqembi (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $585.00 | General |
| Category: Neurology | ||||||
| 11/21/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $114.13 | General |
| Category: Neurology | ||||||
| 11/20/2024 | Eisai Inc. | Leqembi (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $4,680.00 | General |
| Category: Neurology | ||||||
| 11/20/2024 | Eisai Inc. | Leqembi (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $1,462.50 | General |
| Category: Neurology | ||||||
| 11/20/2024 | Eisai Inc. | Leqembi (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $1,462.50 | General |
| Category: Neurology | ||||||
| 11/20/2024 | Eisai Inc. | Leqembi (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $585.00 | General |
| Category: Neurology | ||||||
| 11/20/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $121.84 | General |
| Category: Neurology | ||||||
| 11/12/2024 | Lilly USA, LLC | AMYVID (Drug), KISUNLA | Food and Beverage | In-kind items and services | $24.71 | General |
| Category: Neuroscience | ||||||
| 10/30/2024 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $55.61 | General |
| 10/25/2024 | Lilly USA, LLC | KISUNLA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,600.00 | General |
| Category: Neuroscience | ||||||
| 10/25/2024 | Lilly USA, LLC | KISUNLA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $600.00 | General |
| Category: Neuroscience | ||||||
| 10/23/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $19.09 | General |
| Category: PSYCHIATRY | ||||||
| 10/23/2024 | Lilly USA, LLC | KISUNLA (Drug) | Food and Beverage | In-kind items and services | $16.08 | General |
| Category: Neuroscience | ||||||
| 10/23/2024 | Lilly USA, LLC | KISUNLA (Drug) | Food and Beverage | In-kind items and services | $2.00 | General |
| Category: Neuroscience | ||||||
| 10/18/2024 | Eisai Inc. | — | Food and Beverage | In-kind items and services | $119.45 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 230 | 261 | $63,386 | $34,482 |
| 2022 | 7 | 479 | 551 | $110,596 | $66,279 |
| 2021 | 7 | 530 | 585 | $127,171 | $75,076 |
| 2020 | 8 | 428 | 469 | $174,557 | $46,241 |
Total Patients
1,667
Total Services
1,866
Medicare Billing
$222,077
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 78 | 99 | $23,753 | $13,692 | 57.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 32 | 32 | $8,698 | $5,226 | 60.1% |
| 99483 | Assessment of and care planning for patient with impaired thought processing, typically 60 minutes | Office | 2023 | 25 | 25 | $10,793 | $5,127 | 47.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 42 | 48 | $8,340 | $4,581 | 54.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 35 | 35 | $9,588 | $4,482 | 46.7% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 18 | 22 | $2,214 | $1,374 | 62.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 168 | 228 | $34,065 | $21,478 | 63.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 118 | 118 | $28,478 | $17,524 | 61.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 79 | 88 | $19,898 | $12,245 | 61.5% |
| 99483 | Assessment of and care planning for impaired thought processing, typically 50 minutes | Office | 2022 | 39 | 39 | $15,679 | $8,702 | 55.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 29 | 29 | $6,743 | $3,044 | 45.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 29 | 32 | $3,990 | $2,251 | 56.4% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 17 | 17 | $1,743 | $1,036 | 59.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 175 | 175 | $42,422 | $30,703 | 72.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 150 | 185 | $29,188 | $18,029 | 61.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 108 | 121 | $29,307 | $16,142 | 55.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 46 | 46 | $9,816 | $5,968 | 60.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 13 | 13 | $7,865 | $1,691 | 21.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 24 | 31 | $6,731 | $1,584 | 23.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 14 | 14 | $1,842 | $958.65 | 52.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 138 | 162 | $48,261 | $12,392 | 25.7% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 48 | 48 | $29,371 | $7,355 | 25.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 64 | 70 | $27,795 | $6,964 | 25.1% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 59 | 59 | $24,399 | $6,747 | 27.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 35 | 35 | $21,183 | $5,352 | 25.3% |
About Dr. John Bertelson, M.D
Dr. John Bertelson, M.D is a Behavioral Neurology & Neuropsychiatry healthcare provider based in Austin, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1215959697.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Bertelson, M.D has received a total of $192,897 in payments from pharmaceutical and medical device companies, with $127,470 received in 2024. These payments were reported across 378 transactions from 36 companies. The most common payment nature is "Compensation for serving as faculty or as a speaker for a medical education program" ($91,260).
As a Medicare-enrolled provider, Bertelson has provided services to 1,667 Medicare beneficiaries, totaling 1,866 services with total Medicare billing of $222,077. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Behavioral Neurology & Neuropsychiatry
- Other Specialties Neurology
- Location Austin, TX
- Active Since 07/24/2006
- Last Updated 12/19/2023
- Taxonomy Code 2084B0040X
- Entity Type Individual
- NPI Number 1215959697
Products in Payments
- Leqembi (Drug) $145,551
- KISUNLA (Drug) $11,246
- Adlarity (Drug) $1,040
- REXULTI (Drug) $664.05
- SPRAVATO (Drug) $519.27
- NUPLAZID (Drug) $349.76
- INGREZZA (Drug) $277.85
- AMYVID (Drug) $189.14
- AUSTEDO (Drug) $184.98
- Austedo XR (Drug) $139.31
- TRINTELLIX (Drug) $137.94
- ONGENTYS (Drug) $105.08
- AUBAGIO (Drug) $97.86
- Auvelity (Drug) $95.36
- ADLARITY (Drug) $93.65
- UPLIZNA (Biological) $93.48
- ADUHELM (Biological) $85.98
- VRAYLAR (Drug) $69.92
- ARISTADA (Drug) $64.96
- Dayvigo (Drug) $60.03
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Behavioral Neurology & Neuropsychiatry Doctors in Austin
Padma Kumar, M.d, M.D
Behavioral Neurology & Neuropsychiatry — Payments: $270.53
Behavioral Neurology & Neuropsychiatry $270.53
Robert Turnipseed, M.d, M.D
Behavioral Neurology & Neuropsychiatry — Payments: $95.72
Behavioral Neurology & Neuropsychiatry $95.72
Dr. Barbara Felkins, M.d, M.D
Behavioral Neurology & Neuropsychiatry
Behavioral Neurology & Neuropsychiatry